Freehold, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — MEDIFIRST SOLUTIONS, INC. (MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services, is pleased to announce that Dr. Sanjay Gupta, President of the American Pain Association (APA), is sponsoring a symposium, called “Turn the Tide,” addressing the opioid epidemic. The first symposium will be held on Wednesday, December 12th, at the Philadelphia College of Osteopathic Medicine (PCOM). Medifirst, through its majority owned subsidiary USA Pharma Inc., is working with Dr. Gupta and APA to explore and develop solutions on how Medical CBD can help in this growing crisis.
The APA National Medical School Educational Tour Initiative was formed to educate, advocate and fight the deadly opioid epidemic that has been responsible for killing thousands and putting innocent youths and children at serious risk. Topics to be addressed include: Opioid Epidemic, Pain Management and Medical CBD. The national tour will educate physicians and legislators about the opioid epidemic as well as engage in discussion for insurance coverage for medical CBD for pain relief and treating opioid use disorder.
Two upcoming APA symposiums are scheduled as follows:
1. December 12, 2018, 5-8pm at PCOM Med School, Philadelphia, PA.
2. December 18, 2018, 5-8pm at RWJ University Medical School, New Brunswick, NJ.
Doctors and healthcare professionals are welcome to attend. Please email firstname.lastname@example.org for more information.
Dr. Sanjay Gupta, President of the American Pain Association, stated, “We believe that medical CBD can help treat pain and is quite effective for treating opioid use disorder, having advantages over other options. Part of our mission is addressing the stigma and poor education regarding medical CBD among both physicians and patients. The APA Nationwide Medical School Tour is going to address these issues as well as lobby to get insurance coverage for medical CBD. Most patients can’t afford medical cannabis and as a result, patients choose harmful opioids just because they are paid by insurance plans.”
Medifirst President Bruce J. Schoengood stated that, “Medifirst is committed to battling the pain and opioid crisis that affects so many people. We are pleased to be working with the American Pain Association to seek new and effective solutions for people who suffer from pain every day of their lives.” The Dr. Gupta Pharma medical grade CBD products, to be distributed under the Medifirst majority owned subsidiary USA Pharma, is a line that, we believe, shows great promise for providing an all-natural and effective supplement for pain relief and opioid use disorder. Please note that Dr. Gupta of the APA is not related to Dr. Gupta of CNN.
About The Time Machine Laser
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 – 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
The statements in this press release that relate to the company’s expectations about the future impact on the company’s results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact: Investor Relations
Phone: (732) 786-8044